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Abstract
Background: Follicular variant of papillary thyroid carcinoma (FVPTC) and follicular adenoma (FA) are histologically
closely related tumors and differential diagnosis remains challenging. RNA expression profiling is an established
method to unravel molecular mechanisms underlying the histopathology of diseases.
Methods: BRAF mutational status was established by direct sequencing the hotspot region of exon 15 in six FVPTCs
and seven FAs. Whole-transcript arrays were employed to generate expression profiles in six FVPTCs, seven FAs and
seven normal thyroid tissue samples. The threshold of significance for differential expression on the gene and exon
level was a p-value with a false discovery rate (FDR) < 0.05 and a fold change cutoff > 2. Two dimensional average
linkage hierarchical clustering was generated using differentially expressed genes. Network, pathway, and alternative
splicing utilities were employed to interpret significance of expression data on the gene and exon level.
Results: Expression profiling in FVPTCs and FAs, all of which were negative for a BRAF mutation, revealed 55
transcripts that were significantly differentially expressed, 40 of which were upregulated and 15 downregulated in
FVPTCs vs. FAs. Amongst the most significantly upregulated genes in FVPTCs were GABA B receptor, 2 (GABBR2),
neuronal cell adhesion molecule (NRCAM), extracellular matrix protein 1 (ECM1), heparan sulfate 6-O-sulfotransferase 2
(HS6ST2), and retinoid X receptor, gamma (RXRG). The most significantly downregulated genes in FVPTCs included
interaction protein for cytohesin exchange factors 1 (IPCEF1), G protein-coupled receptor 155 (GPR155), Purkinje cell
protein 4 (PCP4), chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1), and glutamate receptor
interacting protein 1 (GRIP1). Alternative splicing analysis detected 87 genes, 52 of which were also included in the
list of 55 differentially expressed genes. Network analysis demonstrated multiple interactions for a number of
differentially expressed molecules including vitamin D (1,25- dihydroxyvitamin D3) receptor (VDR), SMAD family
member 9 (SMAD9), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), and RXRG.
Conclusions: This is one of the first studies using whole-transcript expression arrays to compare expression profiles
between FVPTCs and FAs. A set of differentially expressed genes has been identified that contains valuable
candidate genes to differentiate both histopathologically related tumor types on the molecular level.
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Introduction
Thyroid cancer is one of the most common cancer types
in the Gulf region and is considered the second most
common cancer in young Saudi women [1]. The majority
of papillary thyroid carcinomas (PTCs) which represent
approximately 80 % of all differentiated thyroid carcino-
mas are histopathologically classified as conventional
PTCs. The follicular variant of PTC (FVPTC) represents
the largest subtype and accounts for about 30 % of all
PTCs [2]. Minor and rare subtypes include tumors such
as Hurthle cell, tall cell, and insular variants of PTCs.
FVPTCs can be distinguished on the molecular level
from the conventional type by an inverse distribution of
mutations affecting key molecules of the mitogen acti-
vated protein kinase (MAKP) pathway. Whereas BRAF
mutations, commonly affecting codon 600 (V600E), are
found in about 40 to 70 % of conventional PTCs, only 10
to 20 % of FVPTCs harbor this mutation [3,4]. In con-
trast, mutations in the highly related RAS genes, HRAS,
KRAS, and NRAS, are identified only sporadically in con-
ventional PTCs but in about 20% of FVPTCs [5].
Whereas a BRAF mutation represents a valuable target
for molecular therapy in advanced solid tumors such like
PTCs, valuable molecular targets in thyroid carcinomas
bearing no BRAF mutation are less known [6]. Further-
more, RAS mutations are not considered as a sole key
event of malignant transformation as they are frequently
present in benign proliferative lesions of the thyroid such
as follicular adenomas (FAs). We have identified RAS
mutations in about 25 % of FAs which is consistent with
findings of other studies [5,7]. It has been a subject of
discussion as to what extent FAs or subtypes of FAs
represent precursor lesions for FVPTCs [8]. Furthermore,
it is of clinical relevance to unambiguously distinguish
FAs from FVPTCs as FA lesions are cured by partial or
(sub)total thyroidectomy whereas a substantial part of
FVPTCs may have progressed further at time of first
clinical treatment which requires clinical follow-up.
Frequency of lymph node metastasis in FVPTC depends
on predictive risk factors as multifocality and invasive
behavior [9]. Criteria to establish a histopathological
diagnosis of FVPTC include cytoplasmic or capsular
invasion and nuclei that are ground glassed and/or
endowed with abundant grooves [10]. A study using
immunohistochemistry identified a panel of markers
including HBME-1, CITED1, galectin-3, cytokeratin 19,
and S100A4 that were able to distinguish FAs from
FVPTCs [8]. Until now, only a few studies compared
expression profiles between benign and malignant thyr-
oid lesions [11-15]. All these studies included different
types of benign or malignant follicular lesions which lim-
its the comparison of the identified gene sets between the
studies. Furthermore, as FVPTCs share histological
features with both PTCs and follicular thyroid carcino-
mas (FTCs) a standardized diagnosis remains challenging
[16,17]. We employed whole-transcript oligonucleotide
microarrays to identify differentially expressed genes
which could gain importance as molecular biomarkers
that separate both follicular lesions on the molecular
level. Normal thyroid specimens were included in expres-
sion profiling to serve as reference for normal expression
levels. A limited number of samples within the compari-
son groups, like in our study, have been successfully used
in other expression studies to generate differentially
expressed gene sets in thyroid cancer [11,13,14].
Methods
Thyroid samples
We studied specimens from six FVPTCs, seven FAs, and
seven normal thyroid (TN) samples that were derived
from patients who were treated surgically in the period
between February 2009 and April 2013 at the King
Abdulaziz University Hospital (KAUH), Jeddah, and the
King Faisal Specialist Hospital & Research Center
(KFSH&RC), Jeddah. Normal thyroid specimens were
derived from unaffected normal thyroid samples. Diagnosis
was established by an experienced oncologic pathologist
(JM) according to established criteria [18,19]. DNA
extraction of all samples and BRAF mutational screening
for the 13 tumor samples was performed as described
earlier [3]. This study was approved by the ethical review
boards of KAUH (no. 358-10) and KFSH&RC (no.
IRB2010-07).
RNA and array processing
Total RNA was extracted from fresh tissue specimens
using the Qiagen RNeasy Mini Kit (Qiagen, Hilden,
Germany). Extraction protocol included an on-column
DNAse treatment as recommended by the manufacturer.
Quality of purified RNA was assessed using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
RNA integrity number for all evaluated samples was at
least 5.0. The NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE) was utilized
to determine RNA concentration. Samples each consisting
of 250 ng RNA were processed using the Ambion WT
Expression Kit (Life Technologies, Austin, TX) and the
GeneChip WT Terminal Labeling and Controls Kit (Affy-
metrix, Santa Clara, CA) according to the manufacturers`
recommendations. In following processing steps the Affy-
metrix GeneChip Hybridization, Wash and Stain Kit was
utilized. The hybridization mixtures containing each 5500
ng of cDNA were hybridized for 17 hrs to Affymetrix
Human Gene 1.0 ST GeneChip arrays in a hybridization
oven at 45°C under rotation (60 rpm). This array type
interrogates with a set of 764,885 probes 36.079 annotated
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reference sequences (NCBI build 36). Subsequent to wash
and staining, the arrays were scanned in the GeneChip
Scanner 3000 7G. Probe cell intensity data (CEL files)
were generated using the GeneChip Command Console
Software (AGCC).
Gene expression and alternative splicing analysis
CEL files were imported to Partek Genomics Suite version
6.6 (Partek Inc., MO) and a log-transformed data set of
robust multi-chip averaged (RMA), background-adjusted,
and normalized values generated using the RMA defaults
settings as configured in the Advanced Import Option
Tab. Quality of experiments was assessed on the basis of
the QC metrics table and QC graphical report. Principal
component analysis (PCA) was performed to assess quality
as well as overall variance in gene expression between
sample groups. Analysis of Variance (ANOVA) was
applied to generate a list of differentially expressed genes
using a false discovery rate (FDR) < 0.05 and a fold change
cut-off >2. FDR is the proportion of false positives among
all positives. In Genomics Suite the step up method was
implemented to control the FDR. Two dimensional aver-
age linkage hierarchical clustering was generated utilizing
Spearman’s correlation as a similarity matrix on the set of
differentially expressed genes (FVPTC vs. FA). To identify
significant genes that intersect or non-intersect between
differentially expressed groups, a Venn diagram was cre-
ated from the Venn diagram menu tab by selecting the
corresponding gene lists. For alternative splicing analysis,
ANOVA was applied to identify probes with differentially
expressed exons using FDR < 0.05 and a fold change cut-
off > 2. The performance of Human Gene 1.0 ST arrays to
detect alternative splicing events has been assessed [20].
The Partek Gene Ontology (GO) enrichment tool was
used in the gene expression workflow to group signifi-
cantly expressed genes (FVPTC vs. FA) into functional
categories in the domains cellular components, molecular
functions, and associated biological processes [21]. The
GO enrichment score indicates the level of differential
expression of genes in a functional category. The score is
determined by utilizing a Fisher`s Exact test to compare
within a GO domain the proportion of genes represented
in a functional category to the proportion not presented in
the functional category. The GO data resources are
curated by the GO consortium in a controlled and struc-
tured vocabulary. The generated array data set complies
with MIAME [22] and has been deposited at the NCBI’s
Gene Expression Omnibus (GEO) under accession num-
ber GSE54958.
Functional network and pathway analysis
The Ingenuity Pathways Analysis software (IPA) (Ingenu-
ity Systems, Redwood City, CA) was employed to interpret
our expression data in more detail. The main features of
IPA are to provide biological insights into a data set by (i)
mapping data to the Ingenuity knowledge base that con-
tains IPA curated and GO information, (ii) translating
data into diseases and biological functions, (iii) creating de
novo molecular networks using algorithms based on biolo-
gical information, (iv) and determining canonical pathways
that are related to the data set. IPA results are sorted and
ranked based on statistic scores. We initiated IPA by
uploading the gene symbols as clone identifiers, p-values,
and fold changes of the set of our differentially expressed
genes. IPA workflow comprised core and functional analy-
sis and structural categorization of the processed data.
Network assembling was based on the connectivity of the
differential expressed genes under the assumption the
higher the connectivity of a gene the more significant it is.
Non-connective areas were filled with genes from the IPA
knowledge base. Canonical pathway analysis included an
overlay analysis of predefined pathways with the gene list.
Results
Using Affymetrix HuGene 1.0 ST arrays we compared
expression profiles of 6 FVPTCs with 7 FAs and used 7
normal thyroid samples for reference expression. Mean
age in both groups was 37 years and besides two male
patients with an FA all other patients were females (Addi-
tional file 1). In FVPTCs, tumor stage I was revealed in
four cases, stage III and stage IV in one case each. No
BRAF mutation was identified in the mutational hotspot
region of exon 15 in all 13 assayed tumors.
Expression of FVPTC vs. FA
Three-D presentation of the PCA demonstrated that FAs
and FVPTCs are clustering closely together as indicated
by the bounding ellipsoids (Figure 1). We identified 55
transcripts that were differentially expressed between FAs
and FVPTCs (p-value with FDR < 0.05 and fold change
cut-off > 2) (Table 1). Forty genes were upregulated and
15 genes downregulated in FVPTCs compared to FAs.
The most upregulated genes in FVPTCs include GABA
acid B receptor, 2 (GABBR2), neuronal cell adhesion mole-
cule (NRCAM), extracellular matrix protein 1 (ECM1),
heparan sulfate 6-O-sulfotransferase 2 (HS6ST2), and reti-
noid X receptor, gamma (RXRG). The most significantly
downregulated genes in FVPTCs include interaction pro-
tein for cytohesin exchange factors 1 (IPCEF1), G protein-
coupled receptor 155 (GPR155), Purkinje cell protein 4
(PCP4), chondroitin sulfate N-acetylgalactosaminyltrans-
ferase 1 (CSGALNACT1), and glutamate receptor interact-
ing protein 1 (GRIP1). In the top five genes that were
overexpressed in FVPTCs, the fold change (range, 4.09-
18.36) was comparably higher than in the top five genes
that were overexpressed in FAs (range, 2.47 - 6.48). Other
genes, all overexpressed in FVPTCs, with a fold change ≥
10 include leucine-rich repeat (kinase 2) (LRRK2), odz, odd
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Figure 1 PCA scatter plot wherein each dot represents a sample with a group specific color. Distance between dots is a dimensional measure
for the similarity of the expression profiles of the samples. Bounding ellipsoids are included for each group.
Table 1 Fifty-five genes differentially expressed between FVPTCs and FAs and comparison with TN sample expression
Gene name Gene symbol FVPTC vs. FA FVPTC vs. TN FA vs. TN
FC1 P2 FC1 P FC1 P
gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2 7.09 1.06E-07 8.51 2.99E-08 1.20 4.10E-01
neuronal cell adhesion molecule NRCAM 4.09 1.64E-07 4.06 1.76E-07 -1.01 9.64E-01
extracellular matrix protein 1 ECM1 18.36 5.77E-07 15.49 1.28E-06 -1.19 6.44E-01
heparan sulfate 6-O-sulfotransferase 2 HS6ST2 5.07 8.60E-07 3.77 1.11E-05 -1.35 1.71E-01
retinoid X receptor, gamma RXRG 13.16 8.69E-07 15.64 3.64E-07 1.19 6.08E-01
insulin-like growth factor 2 mRNA binding protein 2 IGF2BP2 5.88 1.10E-06 4.90 4.45E-06 -1.20 4.40E-01
cellular retinoic acid binding protein 2 CRABP2 4.48 1.18E-06 4.20 2.07E-06 -1.07 7.50E-01
high mobility group AT-hook 2 HMGA2 5.15 1.33E-06 3.17 8.64E-05 -1.62 3.91E-02
interaction protein for cytohesin exchange factors 1 IPCEF1 -6.48 1.39E-06 -3.55 1.32E-04 1.82 2.70E-02
G protein-coupled receptor 155 GPR155 -2.83 2.09E-06 -1.31 8.64E-02 2.16 4.76E-05
Purkinje cell protein 4 PCP4 -2.47 2.17E-06 -1.50 5.96E-03 1.65 9.10E-04
dipeptidyl-peptidase 10 (non-functional) DPP10 3.85 2.22E-06 1.99 2.34E-03 -1.93 2.49E-03
low density lipoprotein receptor-related protein 4 LRP4 8.23 3.70E-06 13.56 2.22E-07 1.65 1.16E-01
chondroitin sulfate N-acetylgalactosaminyltransferase 1 CSGALNACT1 -3.34 4.06E-06 -1.13 5.01E-01 2.95 9.50E-06
fibronectin type III domain containing 4 FNDC4 3.65 5.75E-06 2.48 2.85E-04 -1.47 6.15E-02
leucine-rich repeat kinase 2 LRRK2 20.97 6.06E-06 31.24 1.27E-06 1.49 3.92E-01
odz, odd Oz/ten-m homolog 1 (Drosophila) ODZ1 13.95 6.87E-06 13.63 7.66E-06 -1.02 9.54E-01
lipase, member H LIPH 18.83 7.39E-06 20.52 5.19E-06 1.09 8.49E-01
glutamate receptor interacting protein 1 GRIP1 -2.52 7.61E-06 -1.24 1.66E-01 2.04 9.33E-05
slit homolog 1 (Drosophila) SLIT1 6.12 8.81E-06 9.01 7.51E-07 1.47 1.83E-01
protocadherin 7 PCDH7 3.46 8.83E-06 2.96 4.20E-05 -1.17 4.26E-01
proteolipid protein 1 PLP1 10.00 8.88E-06 4.92 4.63E-04 -2.03 6.14E-02
SOGA family member 3 SOGA3 2.54 9.38E-06 2.44 1.59E-05 -1.04 7.81E-01
patched domain containing 4 PTCHD4 9.30 1.03E-05 3.03 7.04E-03 -3.07 4.90E-03
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosamine GALNT7 3.57 1.04E-05 8.03 1.35E-08 2.25 7.59E-04
glutaminyl-peptide cyclotransferase QPCT 6.05 1.18E-05 5.68 1.79E-05 -1.06 8.27E-01
transcription factor CP2-like 1 TFCP2L1 -4.40 1.42E-05 -1.80 2.95E-02 2.45 1.51E-03
cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) CWH43 -4.73 1.47E-05 -2.32 4.77E-03 2.04 1.10E-02
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Oz/ten-m homolog 1 (Drosophila) (ODZ1), lipase, member
H (LIPH), and proteolipid protein 1 (PLP1).
Hierarchical cluster analysis displays the diverging
expression profiles of the 55 differentially expressed
genes between FAs and FVPTCs (Figure 2). TN samples
were included to provide expression values of normal
thyroid tissue. Comparison of either FVPTCs or FAs with
TN samples revealed 12280 and 11706 differentially
expressed transcripts, respectively. The number of inter-
secting and non-intersecting genes between the three
sets of differentially expressed genes is projected into a
Venn diagram illustrating the molecular relationships
between the groups (Additional file 2).
Enrichment score analysis
An enrichment analysis for functional categories in the
GO domains cellular component, molecular process,
and biological functions was performed on the set of 55
differentially expressed genes (Additional file 3). The
most dominant functional categories in the cellular
component domain were membrane part (enrichment
score 4.90), synapse part (5.73), and membrane (6.16).
In the molecular function domain, the prevalent cate-
gories consisted of molecular transducer activity (2.72),
binding (2.72), and nucleic acid binding transcription
factor activity (2.87) whereas in the biological process
domain, the dominant categories included localization
(5.80), single-organism process (6.03), and developmen-
tal process (10.23).
Exon splicing
Statistical exon splicing analysis identified 62 genes for
which at least one exon was significantly upregulated
and 25 genes for which at least one exon was signifi-
cantly downregulated in FVPTCs compared to FAs
(Additional file 4). This gene list highly overlaps with
the list of differentially expressed genes (Table 1) as 52
of the genes were identical in both sets. An example for
Table 1 Fifty-five genes differentially expressed between FVPTCs and FAs and comparison with TN sample expression
(Continued)
pleiomorphic adenoma gene 1 PLAG1 5.46 1.47E-05 3.88 1.75E-04 -1.41 2.26E-01
UDP-galactose-4-epimerase GALE 2.74 1.52E-05 2.39 8.06E-05 -1.15 4.04E-01
neurotrophic tyrosine kinase, receptor, type 3 NTRK3 3.64 1.75E-05 2.68 3.21E-04 -1.36 1.61E-01
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog KIT -4.84 1.93E-05 -1.47 1.72E-01 3.30 2.53E-04
acid phosphatase, prostate ACPP 2.41 2.59E-0 2.48 1.72E-05 1.03 8.34E-01
diacylglycerol kinase, iota DGKI -3.53 3.16E-05 -1.88 1.19E-02 1.87 9.87E-03
vitamin D (1,25- dihydroxyvitamin D3) receptor VDR 2.62 3.26E-05 2.63 3.09E-05 1.00 9.79E-01
family with sequence similarity 70, member A FAM70A 2.74 3.30E-05 1.05 7.91E-01 -2.61 3.66E-05
uncharacterized LOC100129434 LOC100129434 -2.60 3.63E-05 -1.37 8.73E-02 1.90 1.22E-03
spermatogenesis associated 18 SPATA18 2.70 4.41E-05 1.95 1.93E-03 -1.38 8.18E-02
retrotransposon gag domain containing 4 RGAG4 3.13 4.80E-05 4.19 3.16E-06 1.34 1.66E-01
zinc finger protein 521 ZNF521 2.72 5.44E-05 4.00 1.03E-06 1.47 4.63E-02
pleckstrin and Sec7 domain containing 3 PSD3 3.50 5.69E-05 8.64 5.67E-08 2.47 9.62E-04
synapse differentiation inducing 1 SYNDIG1 -2.67 5.72E-05 -1.47 5.38E-02 1.82 3.60E-03
LIM domain only 3 (rhombotin-like 2) LMO3 2.66 5.86E-05 5.59 4.25E-08 2.10 6.13E-04
adhesion molecule with Ig-like domain 2 AMIGO2 2.87 5.90E-05 2.51 2.35E-04 -1.14 5.02E-01
RNA binding protein with multiple splicing 2 RBPMS2 -2.73 6.11E-05 1.01 9.51E-01 2.76 3.45E-05
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 2.72 6.37E-05 5.15 1.30E-07 1.89 2.75E-03
sodium channel, voltage-gated, type IV, alpha subunit SCN4A 2.29 6.51E-05 2.70 8.15E-06 1.18 2.95E-01
neuro-oncological ventral antigen 1 NOVA1 3.86 7.79E-05 2.49 2.83E-03 -1.55 9.88E-02
SMAD family member 9 SMAD9 -3.03 7.91E-05 -1.18 4.60E-01 2.57 2.66E-04
Sciellin SCEL 5.85 8.10E-05 6.23 5.50E-05 1.07 8.48E-01
SLC26A8 SLC26A8 2.71 8.28E-05 1.45 7.47E-02 -1.87 3.65E-03
serine-rich and transmembrane domain containing 1 SERTM1 -5.94 8.38E-05 -1.58 2.05E-01 3.76 9.96E-04
calpain 3 (p93) CAPN3 2.23 8.41E-05 2.93 2.60E-06 1.32 8.34E-02
immunoglobulin superfamily, member 1 IGSF1 8.63 8.51E-05 9.28 5.97E-05 1.07 8.60E-01
primary ciliary dyskinesia protein 1 PCDP1 -2.17 8.74E-05 -1.23 1.91E-01 1.77 1.15E-03
1FC, fold change;2p-value with FDR < 0.05 and fold change cutoff > 2; -, downregulated in FVPTCs vs. FAs, downregulated in FVPTCs vs. TN, and downregulated
in FAs vs. TN.
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an exon splicing event is provided for HS6ST2 (Addi-
tional file 5).
Network and pathway analysis
Using IPA, a network was assembled based on those con-
nective relationships that were identified in our differen-
tially expressed genes (Figure 3). Upregulated network
molecules in FVPTCs include molecules such as ECM1,
vitamin D (1,25-dihydroxyvitamin D3) receptor (VDR),
NRCAM, and RXRG and downregulated molecules in
FVPTCs include SMAD family member 9 (SMAD9), v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogene homo-
log (KIT), and GRIP1. The most significantly associated
canonical pathway related to the differentially expressed
gene set was thyroid cancer signaling (p = 5.58x10-3).
Discussion
With our gene expression study we were aiming to iden-
tify molecular features that differentiate FVPTC from FA.
We detected a set of significantly differentially expressed
genes that vary from studies comparing FAs with FTCs,
FVPTCs, or PTCs [11,13,14,23,24]. Oligonucleotide micro-
array studies that compared either PTCs/FTCs/FVPTCs
with FAs/hyperplastic lesions [12] or FTCs with FAs [14]
detected 133 and 105 differentially expressed genes,
respectively; however, virtually no genes of these studies
were shared with our 55 differentially expressed genes.
Top genes upregulated in FVPTC
Among the most overexpressed genes in FVPTCs in our
study were GABBR2, NRCAM, ECM1, HS6ST2, RXRG,
LRRK2, ODZ1, LIPH, and PLP1. GABBR2 is a component
of the heterodimeric G protein-coupled receptor for
GABA. Overexpression of GABBR2 has been identified in
pediatric post-Chernobyl PTCs compared to sporadic adult
PTCs [25]. NRCAM is a member of the neuronal cell
adhesion molecules. Prominent overexpression of NRCAM
has been detected in PTCs compared to matched normal
tissue by RT-PCR and immunohistochemistry which led to
the suggestion that the molecule is involved in PTC patho-
genesis [26]. ECM1 is a soluble molecule that is implicated
in angiogenesis and endochondral bone development.
Upregulation of ECM1 has been revealed in malignant
compared to benign thyroid neoplasms and it has been
proven to be useful as a diagnostic marker for thyroid
malignancy in fine needle aspiration biopsies [27]. HS6ST2
is a membrane and extracellular matrix associated mole-
cule. Gene silencing of HS6ST2 in pancreatic cells resulted
in inhibition of cell progression [28]. RXRG is a member of
the retinoid X receptors and forms heterodimers with reti-
noic acid, VDR, and the thyroid hormone receptor. Signifi-
cant overexpression of RXRG has been detected in PTCs
compared normal thyroid tissue and the receptor proved
to be useful in a classifier set consisting of 19 genes to
accurately discriminate PTCs from normal thyroid tissue
[29]. A biostatistics and microarray survey in PTC and
papillary renal cell carcinomas detected concomitant over-
expression of LRRK2 and the MET proto-oncogene [30].
Knockdown of LRRK2 in cell culture experiments mini-
mized MET phosphorylation and impaired MET down-
stream signaling to STAT3 and mTOR resulting in cell
cycle arrest. LRRK2 was considerably higher expressed in
our FVPTCs compared to FAs (fold change, 20.97) under-
scoring the known relevance of the MET pathway in
Figure 2 Hierarchical cluster analysis of 55 genes which were differentially expressed between FAs and FVPTCs. Gene expression of TN samples is
included in analysis. Color scheme, red for comparably higher and blue for comparably lower expression.
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thyroid malignancies [31]. ODZ1 belongs to a conserved
group of signaling molecules acting as transmembrane
receptors and with their intracellular domain as transcrip-
tional factors [32]. An oligonucleotide array study detected
upregulation of ODZ1 in PTCs compared to matched nor-
mal thyroid samples and the results were confirmed by
RT-PCR [33]. The PLP1 protein is a major myelin compo-
nent and a marker for oligodendrocytes. Functional invol-
vement of PLP1 in thyroid cancer is virtually unknown;
however, in glioblastoma multiforme, PLP1 expression cor-
related with the extent of the oligodendroma component
[34]. LIPH is a secreted enzyme that hydrolysis phosphati-
dic acid into free fatty acid and lysophosphatidic acid
which is known as a ligand for a number of G protein-
coupled receptors and implicated in receptor signaling in
cancer [35]. Based on a microarray data survey, LIPH has
been recently discovered as a putative biomarker for lung
adenocarcinomas and bronchioloalveolar carcinomas [36].
LIPH was also found to be higher expressed in the serum
of lung cancer patients.
Top genes downregulated in FVPTC
Among the most downregulated genes in FVPTCs com-
pared to FAs were IPCEF1, GPR155, PCP4, CSGAL-
NACT1, and GRIP1. IPCEF1 has been identified as the
C-terminal part of a protein in which CNK3 represents
the N-terminal part [37]. In vitro experiments have
demonstrated that knockdown of CNK3/IPEF1 leads to
Figure 3 Molecular network analysis based on the set of differentially expressed genes that are known to interact directly or, via intermediate
molecules, indirectly. Molecules like ECM1, SMAD9, KIT, VDR, NRCAM, and RXRG are involved in multiple interactions. Color scheme, red for
comparably higher and green for comparably lower expression in FVPTCs vs. FAs.
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inhibition of hepatocyte growth factor induced cell
migration. GPR155 is an integral membrane G protein-
coupled receptor harboring an auxin efflux carrier
domain, a pleckstrin/G protein-interacting region, and a
winged helix repressor DNA-binding domain; however,
the function of the receptor is barely known [38]. PCP4
codes for a sodium-dependent neurotransmitter. Upre-
gulation of PCP4 was detected in cerebral tissue from
rats that were hyperthyroidic through triiodothyronine
application [39]. CSGALNACT1 is a critical glycosyl-
transferase of chondroitin sulfate biosynthesis. Highest
RNA expression among different tissue types tested was
identified in the thyroid and placenta and statistical net-
work reconstruction on expression data of multiple mye-
loma identified that high expression of CSGALNACT1
was associated with favorable prognosis [40,41]. GRIP1,
also known as nuclear receptor coactivator 2 (NCoA-2)
encodes a transcriptional co-activator of steroid, thyroid,
retinoid, and vitamin D receptors including thyroid hor-
mone receptor alpha [42,43]. GRIP1 assists these nuclear
receptors in promoter-driven DNA expression.
Network genes
Network analysis displayed interactions wherein
approximately one third of our set of 55 differentially
expressed genes participated either in the extracellular
space, transmembrane domain or intracellular compart-
ments (Figure 3). Involved in multiple interactions were
a number of molecules including ECM1, VDR, SMAD9,
KIT, NRCAM, and RXRG. VDR is involved in gene acti-
vation through heterodimerization with the retinoid X
receptor and subsequent binding to vitamin D respon-
sive elements [44]. The functional role of the retinoid X
receptor as a heterodimerization partner of the thyroid
hormone receptor in hormone signaling pathways
depends on the cellular context [45]. Further investiga-
tions should be envisaged to address the functional role
of RXRG, VDR, and the thyroid hormone receptor in
thyroid cancer, especially in FVPTCs. SMAD9 is a mem-
ber of the receptor SMAD family that is involved in the
canonical bone morphogenetic pathway. SMAD9 is
known to interact with high-mobility group AT-hook 2
(HMGA2) for which a higher expression has been
detected in a quantitative RT-PCR assay in FVPTCs and
PTCs compared to FAs [46]. KIT encodes a receptor tyr-
osine kinase type III and activation mutations are asso-
ciated with a number of tumor types; however, decreased
KIT expression has been identified in malignant thyroid
lesions compared to benign lesions [47] which is consis-
tent with our findings.
Nucleic acid binding factors
IGF2BP2 is a member of the insulin-like growth factor
pathway and it has been shown that its expression
correlates with tumor progression in head and neck
squamous cell carcinoma patients [48]. Knockdown of
HGMA2 in embryonic rhabdomyosarcoma cells resulted
in severe downregulation of IGF2BP2 and knockdown of
either HGMA2 or IGF2BP2 led to reduced protein levels
encoded by the neuroblastoma RAS viral (v-ras) onco-
gene homolog (NRAS) [49]. Furthermore, binding of
IGF2BP2 to the 3`UTR of NRAS resulted in increased
stability of the NRAS mRNA and enhanced NRAS pro-
tein levels. As gain-of-function mutations in NRAS are
found in a minority of FVPTCs [5], overexpression of
IGF2BP2 would be an intriguing alternative that leads to
enhanced NRAS signalling in thyroid cancer with folli-
cular histology. CRABP2 is known as a co-activator of
retinoid acid and retinoid acid receptor signaling [50].
Hypermethylation of CpG islands in the CRABP2 pro-
moter was associated with its downregulation in PTC
compared to normal thyroid tissue [51]. We observed a
higher expression of CRABP2 in FVPTCs compared to
FAs but of notice, CRABP2 was lower expressed (fold
change, 1.1) in our FAs compared to TN samples.
TFCP2L1 is a crystallin, alpha B (CRYAB) gene promoter
interacting transcription factor and lower expression of
TFCP2L1 and CRYAB was revealed in anaplastic thyroid
carcinomas compared to benign goiters [52]. Lower
expression of TFCP2L1 was also detected in PTCs com-
pared to matched normal thyroid samples in a combined
microarray/RT-PCR study [53]. The zinc finger factor
PLAG1 is a transcriptional activator of a number of
genes including insulin-like growth factor II and the cyto-
kine-like factor 1[54]. An RT-PCR analysis of a number
of candidate genes for differentiating benign and malig-
nant thyroid lesions detected concordant higher expres-
sion of PLAG1 and HMGA2 in FVPTCs, and to a lesser
extent in FTCs, compared to other thyroid malignancies
(PTCs and a Hurthle cell carcinoma) or benign forms of
proliferative thyroid lesions [15]. A strong correlation of
PLAG1 and HMGA2 expression was also detected in a
number of thyroid carcinomas and uterine leiomyomas
and cell culture experiments led to the conclusion that
HMGA2 is an upstream activator of PLAG1[46]. Expres-
sion of zinc finger transcription factor ZFN521 is known
to be required for embryonic stem cell differentiation
from the epiblast state into neuroectodermal progenitor
cells [55]. Furthermore, cell culture assays indicated that
enhanced expression of ZFN521 is associated with
reduced recognition of tumor cells by natural killer cells
[56]. Downregulation of LMO3 in radiation-related thyr-
oid carcinomas in comparison to matched normal thyr-
oid samples has been detected in a microarray/RT-PCR
study conducted on individuals who received iodine-131
doses as a consequence of the Chernobyl accident [57].
In contrast, overexpression of LMO3 has been demon-
strated as a marker for development and progression of
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neuroblastoma and furthermore, cell culture experiments
indicated that LMO3 is a p53 co-suppressor [58]. In lung
adenocarcinomas bearing a NK2 homeobox 1 (NKX2-1)
amplification, the oncogenic capacity of LMO3 as a tran-
scription regulator downstream of NKX2-1 has been
demonstrated [59]. The neuro-oncological ventral antigen
1 (NOVA1) encodes an alternative splicing factor and is
transcriptionally subject to A-to-I editing [60]. High
expression of the NOVA1 RNA-binding protein has been
found to be associated with unfavorable prognosis in
hepatocellular carcinoma [61].
In summary, our expression profile study identified a
set of candidate genes which are implicated in molecular
mechanisms that differentiate FAs from FVPTCs and
thus, add to our knowledge of the tumor biology of
these histopathologically related, but clinically distinct
entities. Further studies have to address the question to
what extent the identified genes are solely discriminators
of histopathological interest or have functional implica-
tion in a not yet defined transition process from FA to
FVPTC.
Additional material
Additional file 1: Demographic and clinicopathological features of
FA and FVPTC cases.
Additional file 2: A Venn diagram visualizing the number of
differentially expressed genes that intersect or non-intersect
between the comparison groups FVPTC vs. FA, FA vs. TN, and
FVPTC vs. TN. Of the 55 differentially expressed genes in FVPTC vs.
FA, eight were only differentially expressed within this comparison
group whereas other nine genes intersect with FA vs. TN and
another 33 genes intersect with FVPTC vs. TN. Five differentially
expressed genes were shared among all three groups.
Additional file 3: GO enrichmment analysis for the 55 genes that
were differentially expressed between FVPTC and FA. The
functional categories are ranked according to their p-values. (A) In
the cellular component domain, the categories membrane part
(4.90), synapse part (5.73), and membrane (6.16) were prevalent. (B)
In the molecular function domain, the prevalent categories were
molecular transducer activity (2.72), binding (2.72), and nucleic acid
binding transcription factor activity (2.87). (C) In the biological
process domain, the dominant categories were localization (5.80),
single-organism process (6.03), and developmental process (10.23).
Additional file 4: Eighty-seven genes with exons differentially
expressed between FVPTCs and FAs. This is an unfiltered gene list
based on statistics measures and may include genes where, e.g.
different exon expression levels were caused by RNA degradation.
Additional file 5: Exon splicing in heparan sulfate 6-O-
sulfotransferase 2 (HS6ST2). The exons of the gene are interrogated
with nine oligonucleotide probes of which five are highly
overexpressed in FVPTCs compared to FAs and TN samples. Exon
splicing events in HS6ST2 conferring different properties are known
[62].
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